Literature DB >> 8524533

Intrauterine adhesions.

C M March1.   

Abstract

Anticipation and suspicion are critical aspects to any discussion of intrauterine adhesions. Curettage between the second and fourth week postpartum is more likely to cause adhesions than is any other endometrial trauma. Infertility, recurrent abortion, or menstrual aberrations after any uterine trauma should cause the physician to suspect the presence of intrauterine adhesions. Hysterosalpingography and hysteroscopy are the ideal methods to make the diagnosis of IUA, and the latter is the safest, least traumatic, and most precise method of treating adhesions. The addition of an intrauterine splint and high-dose estrogen therapy completes the therapeutic approach. Before attempting conception the cavity should be inspected to verify its normality.

Entities:  

Keywords:  Adhesions; Biology; Contraception; Contraceptive Methods--beneficial effects; Curettage--complications; Diseases; Endoscopy; Examinations And Diagnoses; Family Planning; Genitalia; Genitalia, Female; Gynecologic Surgery; Hysteroscopy; Infertility--women; Iud--beneficial effects; Literature Review; Menstruation Disorders; Obstetrical Surgery; Physical Examinations And Diagnoses; Physiology; Reproduction; Signs And Symptoms; Surgery; Treatment; Urogenital Surgery; Urogenital System; Uterine Effects; Uterus

Mesh:

Substances:

Year:  1995        PMID: 8524533

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  12 in total

1.  Platelet-rich plasma in the management of Asherman syndrome: case report.

Authors:  L Aghajanova; M I Cedars; H G Huddleston
Journal:  J Assist Reprod Genet       Date:  2018-02-17       Impact factor: 3.412

2.  Effect of stem cell application on Asherman syndrome, an experimental rat model.

Authors:  Sevtap Kilic; Beril Yuksel; F Pinarli; A Albayrak; B Boztok; T Delibasi
Journal:  J Assist Reprod Genet       Date:  2014-06-29       Impact factor: 3.412

Review 3.  Efficacy of intrauterine device in the treatment of intrauterine adhesions.

Authors:  Umme Salma; Min Xue; Ali Sheikh Md Sayed; Dabao Xu
Journal:  Biomed Res Int       Date:  2014-09-01       Impact factor: 3.411

4.  Placenta accreta: adherent placenta due to Asherman syndrome.

Authors:  Line Engelbrechtsen; Jens Langhoff-Roos; Jens Joergen Kjer; Olav Istre
Journal:  Clin Case Rep       Date:  2015-01-22

5.  A 10-year Review of the Clinical Presentation and Treatment Outcome of Asherman's Syndrome at a Center with Limited Resources.

Authors:  I U Takai; A S Kwayabura; E A Ugwa; A Idrissa; J Y Obed; M Bukar
Journal:  Ann Med Health Sci Res       Date:  2015 Nov-Dec

6.  The association between menstrual cycle pattern and hysteroscopic march classification with endometrial thickness among infertile women with Asherman syndrome.

Authors:  Saeed Baradwan; Afnan Baradwan; Dania Al-Jaroudi
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

7.  The birth weight in pregnant women with Asherman syndrome compared to normal intrauterine cavity: A case-control study.

Authors:  Saeed Baradwan; Afnan Baradwan; Muhammad Bashir; Dania Al-Jaroudi
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

8.  Reproductive performance of women with and without intrauterine adhesions following recurrent dilatation and curettage for miscarriage: long-term follow-up of a randomized controlled trial.

Authors:  Angelo B Hooker; Robert A de Leeuw; Jos W R Twisk; Hans A M Brölmann; Judith A F Huirne
Journal:  Hum Reprod       Date:  2021-01-01       Impact factor: 6.918

9.  The Diagnosis and Management of Asherman's Syndrome Developed after Cesarean Section and Reproductive Outcome.

Authors:  Pinar Ozcan Cenksoy; Cem Ficicioglu; Mert Yesiladali; Ozge Kizilkale
Journal:  Case Rep Obstet Gynecol       Date:  2013-06-06

Review 10.  The management of Asherman syndrome: a review of literature.

Authors:  Alessandro Conforti; Carlo Alviggi; Antonio Mollo; Giuseppe De Placido; Adam Magos
Journal:  Reprod Biol Endocrinol       Date:  2013-12-27       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.